Tune Therapeutics is an epigenetic programming platform for the treatment of disease.
Tune Therapeutics has raised $175.0M in total funding. The most recent round was Series B. The last funding was announced in January 2025.
Tune Therapeutics's investors include New Enterprise Associates, Hatteras Venture Partners, Mission BioCapital, Yosemite, Emerson Collective.
Tune Therapeutics is headquartered in Durham, United States.
Tune Therapeutics is an epigenetic programming platform for the treatment of disease.
Tune Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Tune Therapeutics — Funding & Investors." VCBacked, January 12, 2025, https://www.vcbacked.co/company/tune-therapeutics. Accessed July 19, 2026.
VCBacked. (2025). Tune Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/tune-therapeutics
{{cite web |title=Tune Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/tune-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated